hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06281795 id: 1.24. briefTitle: Neuromodulation of the Autonomic Nervous System in Athletes acronym: NANSA overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-01-31 date: 2026-01-31 date: 2024-02-28 date: 2024-02-28 name: Bakulev Scientific Center of Cardiovascular Surgery class: OTHER_GOV name: Foundation for the Support of Physical Culture and Sports BECOME A CHAMPION name: Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPION briefSummary: There are few studies in the literature that have evaluated the effects of using percutaneous stimulation of the auricular branch of the vagus nerve for sports purposes (to accelerate recovery after physical exertion). It has been demonstrated that tVNS in athletes improved the rate of heart rate recovery, reduced lactic acid levels in blood plasma, reduced pain, reduced overtraining syndrome and fatigue levels. conditions: Efficacy, Self conditions: Fatigue; Muscle, Heart conditions: Fatigue, Mental conditions: Fatigue; Combat studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1:1 randomization of active stimulation vs. sham stimulation primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 125 type: ESTIMATED name: tVNS measure: Dynamics of maximum oxygen consumption (VO2max). measure: The dynamics of the treadmill speed at the level of the anaerobic threshold of metabolism. measure: Dynamics of the treadmill speed at the level of the aerobic metabolism threshold of metabolism. measure: The dynamics of the heart rate (HR) at the level of the anaerobic threshold of metabolism. measure: The dynamics of the heart rate (HR) at the level of the aerobic threshold of metabolism. measure: The dynamics of RMSSD. measure: HF dynamics measure: Dynamics of the LF/HF ratio. sex: ALL minimumAge: 15 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPION city: Krasnodar country: Russian Federation lat: 45.04484 lon: 38.97603 hasResults: False
nctId: NCT06281782 id: PRP with topical retinoids briefTitle: Platelet-rich Plasma With Topical Retinoids Versus Topical Retinoids Alone in Acne Vulgaris overallStatus: RECRUITING date: 2024-01-01 date: 2024-04 date: 2024-05 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: Acne vulgaris is the most common skin disease in adolescents and young adults. Adult or post-adolescent acne occurs in 12-14% of this population.It is a chronic, inflammatory disease of the pilosebaceous unit .The clinical features of acne include seborrhoea, non-inflammatory lesions (open and closed comedones), inflammatory lesions (papules and pustules), and various degrees of scarring.
Platelet-rich plasma (PRP) is prepared by simple centrifugation of whole blood to concentrate platelets and simultaneously remove red blood cells. The resultant supernatant is the PRP that contains various growth factors, including platelet-derived growth factor (PDGF), transforming growth factor (TGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF).These growth factors are involved in the healing of soft tissue and can regulate cellular processes such as chemotaxis, angiogenesis, mitogenesis, differentiation, and metabolism .
Topical retinoids are used in the treatment of both noninflammatory and inflammatory acne.Food and Drug Administration (FDA) approved three topical retinoids: adapalene, tazarotene, and tretinoin. These agents help normalize follicular keratinization and decrease keratinocyte cohesiveness, thereby reducing follicular occlusion and comedon formation .Topical retinoids also compete with factors involved in the acne inflammation response, enhance penetration of other topical acne medications, and accelerate the resolution of acne-induced post-inflammatory hyperpigmentation.
PRP with topical retinoids will be evaluated and campared with topical retinoids alone in acne tretment. conditions: Acne Vulgaris studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Topical retinoids versus topical retinoids wit PRP in acne vulgaris treatment primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: topical retinoids and platalet rich plasma measure: change of acne lasions sex: ALL minimumAge: 12 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: Faculty of Medicine status: RECRUITING city: Assiut country: Egypt name: Howida Abdalla role: CONTACT email: d.howida@windowslive.com lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06281769 id: NL82101.000.22 briefTitle: Prostate Cancer Detection Rate of Targeted Biopsies With PCaVision overallStatus: RECRUITING date: 2024-02-26 date: 2025-01-01 date: 2025-01-01 date: 2024-02-28 date: 2024-03-06 name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) class: OTHER name: Angiogenesis Analytics briefSummary: The primary objective is to demonstrate non-inferiority of the detection rate of clinically significant prostate cancer (csPCa) in targeted biopsies based on PCaVision imaging (PCaVision pathway) in comparison with the detection rate of clinically significant cancer in targeted biopsies based on MRI (MRI pathway). conditions: Prostate Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 438 type: ESTIMATED name: 3D multi-parametric ultrasound targeted biopsy pathway using PcaVision name: MRI targeted biopsy pathway measure: Detection rate of clinically significant prostate cancer (csPCa) in targeted biopsies based on PCaVision imaging in comparison with the detection rate of clinically significant cancer in targeted biopsies based on MRI. measure: Proportion of men in whom targeted biopsies could be safely omitted in the PCaVision pathway versus the MRI pathway. measure: Detection rate of three different definitions of prostate cancer in targeted biopsies based on PCaVision imaging (PCaVision pathway) in comparison with the detection rate of targeted biopsies based on MRI (MRI pathway). measure: Number of men in whom the PCaVision pathway generated insufficient quality images with the number of men with insufficient quality MRI images in the MRI pathway. measure: Detection rate of clinically significant prostate cancer in targeted biopsies based on PCaVision imaging using various incremental levels of PCaVision's image quality requirements in comparison with the detection rate of targeted biopsies based on MRI. sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Amsterdam UMC - location VUmc status: RECRUITING city: Amsterdam country: Netherlands lat: 52.37403 lon: 4.88969 facility: Andros Clinics status: RECRUITING city: Baarn country: Netherlands lat: 52.21167 lon: 5.2875 facility: Spaarne Gasthuis status: RECRUITING city: Hoofddorp country: Netherlands lat: 52.3025 lon: 4.68889 facility: St. Antonius status: RECRUITING city: Nieuwegein country: Netherlands lat: 52.02917 lon: 5.08056 facility: Fransiscus Gasthuis status: RECRUITING city: Rotterdam country: Netherlands lat: 51.9225 lon: 4.47917 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-12-15 uploadDate: 2024-01-12T04:56 filename: Prot_SAP_000.pdf size: 1638356 hasResults: False
nctId: NCT06281743 id: LST-Ped Survey briefTitle: Attitudes to Decisions to Withdraw or Withhold Life-sustaining Treatments in Critically Ill Children acronym: LSTPedSurvey overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-12 date: 2026-12 date: 2024-02-28 date: 2024-03-15 name: Göteborg University class: OTHER briefSummary: The aim of this study is to investigate attitudes on decisions to withdraw or withhold life-sustaining treatments in critically ill children in Swedish intensive care units. This is a survey among pediatric critical care physicians. conditions: Pediatric Disorder conditions: Critical Illness conditions: Ethics, Narrative studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Survey measure: Attitudes and experiences -questionnaire sex: ALL minimumAge: 1 Year maximumAge: 100 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06281730 id: 23-009197 briefTitle: Use of New Generation Fetoscopes in Pregnancies Affected by Fetal Diseases Amenable to Fetoscopy Therapy overallStatus: RECRUITING date: 2024-05 date: 2044-02 date: 2044-02 date: 2024-02-28 date: 2024-04-09 name: Mayo Clinic class: OTHER briefSummary: The Researchers are trying to determine feasibility and safety of performing surgery in the womb with the Karl Storz fetoscopes (a tool used to access the baby in the body of the mother). This are new and improved fetoscopes that are not yet approved by the FDA. conditions: In Utero Procedure Affecting Fetus or Newborn studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: Karl Storz New Generation Fetoscope - curved 11508AAK name: Karl Storz New Generation Fetoscope - straight 11506AAK measure: Adverse events measure: Serious Adverse Events measure: Device malfunctions measure: Mean gestational age at delivery measure: Successful Completion measure: Satisfaction scores measure: Live births measure: Neonatal deaths sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic Minnesota status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06281717 id: IRB-P00045047 briefTitle: A Pilot Study on the Role of Fetal Endotracheal Occlusion (FETO) in Fetuses With Severe Congenital Diaphragmatic Hernia overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2027-03-01 date: 2030-08-30 date: 2024-02-28 date: 2024-02-28 name: Alireza Shamshirsaz class: OTHER briefSummary: The goal of this pilot trial is to learn more about the role of Fetal Endotracheal Occlusion (FETO) as an intervention in fetuses with severe congenital diaphragmatic hernia (CDH). The research team will investigate the feasibility and safety of the FETO procedure, as well as determine whether FETO can improve lung growth before birth, and survival after birth.
This study will enroll 10 pregnant participants to undergo the FETO procedure at a gestational age of 27 weeks 0 days to 29 weeks 6 days. The participant will be monitored for a few weeks, and then the FETO removal procedure will be performed ideally at 34 weeks 0 days to 34 weeks 6 days, but may be indicated earlier as determined by the Maternal Fetal care team. The pregnant participant and their baby will continue to be monitored during delivery and up until the child reaches 2 years of age. conditions: Congenital Diaphragmatic Hernia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Fetal Endotracheal Occlusion (FETO) measure: Successful Ballon Placement measure: Successful Balloon Removal measure: Balloon placement operative time measure: Balloon removal operative time measure: Type of FETO release measure: Maternal Complications measure: Gestational age at delivery measure: Fetal lung volume measure: O/E LHR measure: Infant survival measure: Oxygen dependency measure: Number of infants requiring ECMO measure: NICU stay measure: Ventilator support measure: Presence of periventricular leukomalacia measure: Presence of neonatal sepsis measure: Presence of intraventricular hemorrhage measure: Retinopathy of prematurity measure: Presence of gastro-esophageal reflux measure: CDH repair type measure: Pulmonary function measure: Infant Neurodevelopment measure: Route of delivery measure: Maternal hospitalization sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Boston Children's Hospital city: Boston state: Massachusetts zip: 02115 country: United States name: Brittany Gudanowski role: CONTACT phone: 617-919-6658 email: Brittany.Gudanowski@childrens.harvard.edu name: Maternal Fetal Care Center role: CONTACT phone: 617-355-6512 email: MFCCFetalResearchStudies-dl@childrens.harvard.edu name: Alireza Shamshirsaz, MD role: PRINCIPAL_INVESTIGATOR name: Eyal Krispin, MD role: SUB_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06281704 id: AK101-102 briefTitle: A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis overallStatus: COMPLETED date: 2020-11-26 date: 2022-05-17 date: 2022-12-31 date: 2024-02-28 date: 2024-02-28 name: Akeso class: INDUSTRY briefSummary: This is a Phase Ib clinical study to evaluate the safety, tolerance, pharmacokinetics and efficacy of AK101 in subjects with moderately to severely active ulcerative colitis. conditions: Ulcerative Colitis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 34 type: ACTUAL name: AK101 IV name: AK101 SC name: Placebo name: AK101 IV/AK101 SC measure: Adverse Events measure: Adverse Events measure: Elimination half-life (T1/2) of AK101 measure: Mean residence time (MRT) of AK101 measure: Area under curve (AUC) of AK101 measure: Apparent distribution volume (VD/F) of AK101 measure: Systemic clearance (CL/F) of AK101 measure: Maximum (peak) plasma concentration (Cmax) of AK101 measure: Time to maximum plasma concentration (Tmax) of AK101 measure: Proportion of subjects with clinical response at Week8(per Adapted Mayo Score without physician's global assessment). measure: Proportion of subjects with clinical response at Week8(per the Mayo score). measure: Immunogenicity index sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Bengbu Medical College city: Bengbu state: Anhui zip: 233099 country: China lat: 32.94083 lon: 117.36083 facility: Peking Union Medical College Hospital city: Beijing state: Beijing zip: 100730 country: China lat: 39.9075 lon: 116.39723 facility: The First Affiliated Hospital of Fujian Medical University city: Fuzhou state: Fujian zip: 350004 country: China lat: 26.06139 lon: 119.30611 facility: Nanfang Hospital city: Guangzhou state: Guangdong zip: 510515 country: China lat: 23.11667 lon: 113.25 facility: The Sixth Affiliated Hospital of Sun Yat-Sen University city: Guanzhou state: Guangdong zip: 510665 country: China facility: The Second Hospital of Hebei Medical University city: Shijiazhuang state: Hebei zip: 050004 country: China lat: 38.04139 lon: 114.47861 facility: People's Hospital of Wuhan University city: Wuhan state: Hubei zip: 430060 country: China lat: 30.58333 lon: 114.26667 facility: Nanjing First Hospital city: Nanjing state: Jiangsu zip: 210012 country: China lat: 32.06167 lon: 118.77778 facility: The Affiliated Hospital of Xuzhou Medical University city: Xuzhou state: Jiangsu zip: 221004 country: China lat: 34.18045 lon: 117.15707 facility: Shengjing Hospital of China Medical University city: Shengyang state: Liaoning zip: 110000 country: China facility: Ruijin Hospital, Shanghai Jiaotong University School of Medicine city: Shanghai state: Shanghai zip: 200025 country: China lat: 31.22222 lon: 121.45806 facility: Tianjing People's Hospital city: Tianjing state: Tianjing zip: 300122 country: China hasResults: False
nctId: NCT06281691 id: GreenBladder briefTitle: GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit overallStatus: ENROLLING_BY_INVITATION date: 2023-04-28 date: 2024-07-01 date: 2025-11-30 date: 2024-02-28 date: 2024-02-28 name: Jørgen Bjerggaard Jensen class: OTHER name: Cepheid name: Laborie Medical Technologies Inc. name: Vingmed Danmark A/S name: OneMed A/S briefSummary: The goal of this observational study is to evaluate whether a urinary biomarker (Xpert® Bladder Cancer Detection Test) can be used as a selection tool to decide which patients that should undergo cystoscopy in haematuria work-up or in other indications where bladder tumor is suspected. Hereby, the investigators will investigate in which patients where cystoscopy can be omitted, particularly in areas with limited access to urological service. With these more selected investigations, patients with bladder tumors will potentially be selected to earlier diagnosis compared to the current non-selected investigations with the inherent logistic and economical challenges. With this strategy, the investigators aim at improving the current poor prognosis for bladder cancer patients in Greenland. conditions: Urinary Bladder Neoplasms studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Xpert® Bladder Cancer Detection Test measure: Accuracy of urinary marker (Xpert Bladder Cancer Detection Test) in patients undergoing cystoscopy for bladder cancer investigation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Urology, Aarhus University Hopsital city: Aarhus zip: 8000 country: Denmark lat: 56.15674 lon: 10.21076 facility: Queen Ingrid's Hospital city: Nuuk zip: 3900 country: Greenland lat: 64.18347 lon: -51.72157 hasResults: False
nctId: NCT06281678 id: CIBI363A202 briefTitle: A Study of IBI363 in Subjects With Advanced Solid Malignancies overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-03-01 date: 2026-12-31 date: 2024-02-28 date: 2024-02-28 name: Innovent Biologics (Suzhou) Co. Ltd. class: INDUSTRY briefSummary: This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies. conditions: Solid Tumors studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 160 type: ESTIMATED name: IBI363 measure: Objective response rate (ORR) measure: Adverse Event （AE） measure: Dose-limiting Toxicity （DLT） sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Kansas Medcial Center Research Institute city: Fairway state: Kansas zip: 66205 country: United States name: Saqib Abbasi role: CONTACT phone: 913-945-7545 email: sabbasi@kumc.edu lat: 39.02223 lon: -94.6319 hasResults: False
nctId: NCT06281652 id: Cognichess briefTitle: Cognitive Intervention With Go and Chess in Early and Subjective Cognitive Decline acronym: Cognichess overallStatus: RECRUITING date: 2024-02-13 date: 2025-02-13 date: 2025-02-13 date: 2024-02-28 date: 2024-03-01 name: University of Milano Bicocca class: OTHER briefSummary: The goal of this clinical trial\]is to evaluate if learning to play traditional board games could improve cognition in subjects with mild cognitive impairment and subjective cognitive decline. The main questions it aims to answer are:
* Control group conditions: Mild Cognitive Impairment conditions: Subjective Cognitive Decline studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 80 type: ESTIMATED name: Go classes name: Chess classes measure: General cognition measure: Digit Span Forward measure: Digit Span Backwards measure: Trail Making Test - part A measure: Trail Making Test - part B measure: Semantic fluency measure: Quality of life indicator measure: Depression measure: Lifestyle sex: ALL minimumAge: 55 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS San Gerardo dei Tintori status: RECRUITING city: Monza state: Lombardia zip: 20900 country: Italy name: Lucio Tremolizzo, MD, PhD role: CONTACT phone: +390392339082 email: lucio.tremolizzo@unimib.it name: Federico Emanuele Pozzi, MD role: SUB_INVESTIGATOR lat: 45.58005 lon: 9.27246 hasResults: False
nctId: NCT06281639 id: RAPID briefTitle: RAPID: a Comparison Study of a Novel Ultrasound Device of Automated Congenital Heart Imaging overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-04-01 date: 2024-02-28 date: 2024-02-28 name: University of Minnesota class: OTHER briefSummary: The RAPID ultrasound is a portable imaging device that captures a one point image from the subcostal region of the heart. The device is set on the patient's chest and captures the image in \<1 minute. It uses ultrasound imaging energy that is similar to commercialized devices and safe for patients of all ages and sizes. The device is a non-significant risk and therefore will not require an IDE. Images from RAPID will be taken directly before or after the standard clinical PCU. Images taken from both the RAPID device and the standard PCU will be de-identified and stored securely in BOX for review by two independent cardiologists. Image reviews will be conducted within Box. conditions: Congenital Heart Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: RAPID measure: RAPID imaging quality sex: ALL maximumAge: 1 Year stdAges: CHILD facility: University of Minnesota city: Minneapolis state: Minnesota zip: 55414 country: United States name: Gwenyth Fischer, MD role: CONTACT phone: 612-625-6678 email: fisch662@umn.edu lat: 44.97997 lon: -93.26384 hasResults: False
nctId: NCT06281626 id: 2024_RIPH_01_Preservatif briefTitle: Use of the Free Male Condom Scheme in Young Adults Aged 18 to 25 acronym: Préservatif overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-05-01 date: 2024-10-01 date: 2024-02-28 date: 2024-02-28 name: Université de Reims Champagne-Ardenne class: OTHER briefSummary: For several years, the incidence of sexually transmitted infections (STIs) has been rising sharply, while that of HIV has stagnated. This is due to the decline in condom use since the late 1990s, despite the fact that condom are considered the only effective way to prevent STIs.
In France, 40% of STIs concern young people aged 15 to 25. The national public health strategy aims to stem the circulation of HIV and eliminate STIs as a major public health problem by 2030. To achieve this, several measures have been implemented: reimbursement of male condoms on prescription (2018), 100% free contraception and prevention in sexual health consultation (2021), and more recently, free, non-prescription access to male condoms in pharmacies (end 2022). conditions: Comdom studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 2000 type: ESTIMATED name: Data collection measure: use of free male condoms sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Ufr Medecine Urca city: Reims zip: 51100 country: France lat: 49.25 lon: 4.03333 facility: Université de Reims Champagne Ardenne city: Reims zip: 51100 country: France lat: 49.25 lon: 4.03333 hasResults: False
nctId: NCT06281613 id: 2024-AMCOPTEO briefTitle: Comparison of AMCOP Bioactivator and High-pull Headgear in Treating Skeletal Class II Hyperdivergent Pediatric Patients overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-03 date: 2024-04-01 date: 2024-04-05 date: 2024-02-28 date: 2024-03-08 name: University of Pavia class: OTHER briefSummary: The aim of the present study was to retrospectively compare the clinical use of high-pull headgear versus AMCOP bioactivators for hyperdivergent pediatric patients.